for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Olympus Corp

7733.T

Latest Trade

2,515.00JPY

Change

50.00(+2.03%)

Volume

3,564,700

Today's Range

2,469.00

 - 

2,519.00

52 Week Range

1,883.50

 - 

2,519.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,465.00
Open
2,488.00
Volume
3,564,700
3M AVG Volume
66.24
Today's High
2,519.00
Today's Low
2,469.00
52 Week High
2,519.00
52 Week Low
1,883.50
Shares Out (MIL)
1,285.64
Market Cap (MIL)
3,267,725.00
Forward P/E
31.89
Dividend (Yield %)
0.48

Next Event

Q2 2022 Olympus Corp Earnings Release

Latest Developments

More

Olympus Corp - To Retire Treasury Shares Worth 5.22% Of Outstanding Stock On June 4

Olympus Corp - Acquisition Of Quest Photonic Devices B.V. In Netherlands

Olympus Says It Will Buy Veran Medical Technologies For $300 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Olympus Corp

Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, science, video and other products. The Company operates in five business segments. The Endoscopy segment provides gastrointestinal endoscopy, surgical endoscopy, endoscopy systems and repair services. The Therapeutic Equipment segment provides endoscopic treatment tools, energy devices, urology, gynecology and otolaryngology products. The Scientific segment provides biological microscope, industrial microscope, industrial endoscope and non-destructive inspection equipment. The Imaging segment provides digital cameras and recording machines. The Others segment is engaged in the manufacture and sale of biomaterials. The Company is also engaged in the financial investment business.

Industry

Medical Equipment & Supplies

Contact Info

Shinjuku Monolith, 2-3-1, Nishi-Shinjuku

SHINJUKU-KU, TKY

163-0914

Japan

+81.3.33402111

https://www.olympus.co.jp/

Executive Leadership

Yasuo Takeuchi

President, Chief Executive Officer, Representative Executive Officer, Chairman of Subsidiary, Director

Chikashi Takeda

Chief Financial Officer, Executive Officer

Nacho Abia

Chief Operating Officer, Executive Officer, Chief Executive Officer of Subsidiary

Akihiro Taguchi

Executive Officer, Chief Technology Officer

Stefan Kaufmann

Chief Administrative Officer, Executive Officer, Director

Key Stats

1.88 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2019

0.8K

2020

0.8K

2021

0.7K

2022(E)

0.8K
EPS (JPY)

2019

5.970

2020

39.370

2021

10.050

2022(E)

78.374
Price To Earnings (TTM)
38.29
Price To Sales (TTM)
4.16
Price To Book (MRQ)
8.08
Price To Cash Flow (TTM)
22.55
Total Debt To Equity (MRQ)
83.69
LT Debt To Equity (MRQ)
80.89
Return on Investment (TTM)
10.48
Return on Equity (TTM)
7.54

Latest News

Latest News

In Japan Inc, activist investors come in from the cold

Yasuo Takeuchi remembers the horror he felt in 2017 when, as chief financial officer of Japan's Olympus Corp, he was told an activist investor had taken a stake in the company: the barbarians were at the gate.

Chip materials maker JSR to nominate ValueAct exec to board

Japanese chip and display materials maker JSR Corp said on Monday it will nominate a partner of activist investor ValueAct Capital to be an external board director, a rare move in the country where activists are still viewed with suspicion by many.

Shell curtails production at Olympus platform due to storm

Royal Dutch Shell Plc on Sunday said production is being curtailed at its Olympus oil and natural gas platform in the Gulf of Mexico to prepare for potential impacts from Tropical Storm Sally.

Olympus says to sell camera business to Japan Industrial Partners

Japan's Olympus Corp said on Wednesday it had agreed to sell its loss-making camera business dating back 84 years to Japan Industrial Partners Inc.

BRIEF-Olympus Corp - To Postpone Announcement Of Financial Forecasts For Fy2020/21Originally Scheduled For June 24

* OLYMPUS CORP - TO POSTPONE ANNOUNCEMENT OF FINANCIAL FORECASTS FOR FY2020/21ORIGINALLY SCHEDULED FOR JUNE 24

BRIEF-Urogen Announces Positive Data From Pivotal Olympus Trial Evaluating Jelmyto In Patients With Low-Grade Upper Tract Urothelial Cancer

* UROGEN ANNOUNCES POSITIVE DATA FROM PIVOTAL OLYMPUS TRIAL EVALUATING JELMYTO™ IN PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Sony in $760 million Olympus stake sale after investor Loeb's prodding

Sony Corp <6758.T> is selling its 5% stake in Olympus Corp <7733.T> back to the Japanese medical equipment maker for 80.4 billion yen ($762.88 million), a move that Daniel Loeb's activist hedge fund Third Point LLC had called for.

Japan's Olympus to buy back 5% stake from Sony

Japanese endoscope maker Olympus Corp said on Thursday it will buy back 68.9 million shares, or a 5.03% stake, from Sony Corp.

Ex-Olympus executive avoids prison in case over infection-linked scopes

A former executive of a subsidiary of Japan's Olympus Corp avoided prison on Wednesday after admitting he failed to file necessary reports with U.S. regulators about infections linked to a widely-used type of medical scope it made.

Olympus whistleblower Woodford wins London pensions lawsuit

The former CEO of Olympus, who blew the whistle on a $1.7 billion accounting scandal at the Japanese medical equipment maker in 2011, has won a London court battle over alleged wrongdoing linked to his 64-million-pound ($85-million) pension.

Japan's Olympus to propose board seat for activist investor ValueAct

Japan's Olympus Corp <7733.T> said it would propose to give top shareholder U.S. hedge fund ValueAct Capital a seat at its board, a rare move in the country where activists are still viewed by companies as asset-strippers to be resisted.

Nikkei ends firmer on positive trade talks; Olympus jumps 8.4 pct

* Olympus surges after two brokerages raise their stock ratings

Nikkei gains on hopes for U.S.-China talks, Olympus leaps 7.6 pct

* Olympus jumps after two brokerages raise their stock ratings

Olympus unit pleads guilty to resolve U.S. duodenoscope probe

An Olympus Corp subsidiary pleaded guilty on Monday and agreed to pay $85 million to resolve charges that it failed to file reports with U.S. regulators regarding infections connected to its duodenoscopes while continuing to sell the medical devices used to view the gastrointestinal...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up